Evaluation of United Kingdom (UK)-Windsor Framework and Comparison Against European Union (EU) Regulations for Medicines Regulation.

Abstract

The United Kingdom (UK)'s regulatory profile is changing following the UK's exit from the European Union (EU). As a consequence, the Medicines and Healthcare products Regulatory Agency (MHRA) became more independent. Since then, numerous attempts have been made to ease the separation of the UK from the European Union, focusing mainly on Northern Ireland (NI), which is part of the UK but shares a land border with the EU. The Windsor Framework facilitates the relationship between the EU and the UK, including the role of the European Medicines Agency (EMA) and MHRA in NI. The review throws light on the implementation of the Windsor Framework detailing the key aspects, and the pre- and post-implementation changes in Northern Ireland, Great Britain and the Republic of Ireland. The Framework is useful for industries such as pharmaceuticals where regulatory approval and an uninterrupted supply chain are critical. Evaluating the Framework illuminate's areas for improvement, threats, and scope for cooperation between the UK and EU authorities. The review details efficiency, costs, and market accessibility of medicines, to give a better representation of the regulatory position in NI. The study reveals the pros and cons of the Framework, to assist stakeholder evaluation of Marketing Authorisation Holders (MAHs) that have registered both in UK and EU markets.